“It was a no-brainer”: A qualitative study of factors driving previvors’ decision-making when considering risk-reducing salpingectomy with delayed oophorectomy

Caroline Gellman a,*, Charlotte Ezratty a, Julia Schwarz a, Valentin Kolev b, Stephanie V. Blank b,c

a Icahn School of Medicine at Mount Sinai, New York, NY, United States
b Department of Obstetrics, Gynecologic and Reproductive Science, Division of Gynecologic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
c Blavatnik Family Women’s Health Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States

ARTICLE INFO

Keywords:
BRCA
Lynch syndrome
Risk-reducing salpingectomy with delayed oophorectomy
Ovarian cancer risk reduction
Qualitative research

ABSTRACT

Objective: Previvors are becoming more aware of the option of risk-reducing salpingectomy with delayed oophorectomy (RRS-DO) to mitigate their risk of ovarian cancer. In this qualitative study, we explored the clinical and non-clinical factors that impacted previvors’ decision-making to pursue RRS-DO as a risk reduction strategy.

Methods: Semi-structured telephone interviews were conducted with previvors and transcribed verbatim. Using ATLAS.ti® software, two primary investigators interpreted data through thematic analysis. After coding four interviews, the investigators discussed discrepancies between codes with a moderator and resolved and refined code. The investigators applied the universal codebook to all interviews and revised the codebook using an iterative approach. Examining codes within and across interviews allowed for major themes and patterns to emerge.

Results: Interviews were conducted with seventeen previvors (ages 31–46). 6 (25%) previvors had a BRCA1 mutation, 7 (41%), a BRCA2 mutation, 3 (13%), a Lynch-related mutation, and 1 (6%), other (MUTYH mutation). At the time of interview, 12 previvors (71%) were planning (6) or had undergone (6) RRS-DO, 4 (23%) were planning (1) or had undergone (3) risk reducing salpingo-oophorectomy (RRSO), and 1 (6%) was undecided. Three major themes emerged: motivating factors for selecting surgical risk reduction option, barriers complicating surgical decision-making, and facilitating factors for surgical decision-making. RRS-DO-focused previvors prioritized avoiding menopause, and they also emphasized that self-advocacy and building rapport with providers facilitated their decision-making.

Conclusion: By understanding previvors’ priorities and experiences, physicians can better partner with previvors as they navigate their ovarian cancer risk reduction journey. This will ultimately optimize shared decision-making.

1. Introduction

People with hereditary breast and ovarian cancer syndrome (HBOC) have an elevated risk for developing breast and ovarian cancer (Lancaster et al., 2007; Chen and Parmigiani, 2007; Antoniou et al., 2003). By age 70, people with a mutation in the BRCA1 gene have a 39–46% risk for developing ovarian cancer, and people with a mutation in the BRCA2 gene have a 10–27% risk (King et al., 2003). In comparison, the general population has a lifetime risk of 1.2% (SEER, 2021).

Screening with CA-125 and transvaginal ultrasound (TVUS) has little utility in reducing ovarian cancer mortality (Pinsky et al., 2017; Fishman et al., 2005; Menon et al., 2009). Consequently, the National Comprehensive Cancer Network (NCCN) recommends risk-reducing salpingo-oophorectomy (RRSO) to mitigate risk for people with HBOC (Daly et al., 2021). Studies have evaluated outcomes after RRSO, demonstrating a decrease in ovarian cancer risk and an overall survival benefit (Kauf et al., 2002; Rebeck et al., 2002; Kauff et al., 2008; Finch et al., 2006; Grann et al., 2002). The NCCN recommends that people...
with a BRCA1 mutation undergo RRSO at ages 35–40 and people with a BRCA2 mutation undergo RRSO at ages 40–45 (Daly et al., 2021).

Despite recommendations, many with HBOC are reluctant to undergo RRSO at the recommended age (Holman et al., 2014). In light of accumulating evidence that BRCA1/2-associated ovarian tumors originate in the fallopian tube (Crum et al., 2007; Callahan et al., 2007; Leeper et al., 2002; Medeiros et al., 2006; Powell et al., 2005; Lu et al., 2000; Colgan et al., 2001; Yates et al., 2011; Jarboe et al., 2008; Kurman and Shih, 2010), some providers are now offering risk reducing salpingectomy with delayed oophorectomy (RRS-DO) as an alternative for these high-risk individuals (Swanson and Bakkum-Gamez, 2016). While RRS-DO is not currently accepted as standard of care, the WISP (NCT02760849), TUBA (NCT02321228), PROTECTOR (ISRCTN25173360), and SOROCK (NCT04251052) trials are prospective, multicenter trials investigating the outcomes associated with RRS-DO (M.D. Anderson Cancer Center, 2019; Harmsen et al., 2015; Gaba et al., 2021; NRG Oncology, 2021).

While previvors, people with HBOC, are increasingly aware of the option of RRS-DO to manage their genetic cancer risk, there are few studies assessing why previvors might choose RRS-DO over RRSO. In this study, we aimed to better understand the factors, both clinical and non-clinical, that contributed to previvors’ decisions to select RRS-DO as a risk reduction strategy.

2. Methods

This study was determined exempt by The Human Research Protection Program at the Icahn School of Medicine at Mount Sinai (ISMMS). Research methods were designed in consultation with a qualitative research expert.

2.1. Participants

Participants were referred by physicians at the Mount Sinai Hospital Campus and the Blavatnik Family Chelsea Medical Center at Mount Sinai. Participants were eligible if they were considering or had considered RRS-DO and if they had a documented deleterious mutation in one of the following genes associated with ovarian cancer: BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MTHYH, or Lynch-associated genes. All patients who met this eligibility criteria and presented to participating providers between June through September 2020 were invited to participate. Previvors who were planning RRSO or who had already completed RRSO were included as well to allow for further exploration of the tension arising in the surgical decision-making process.

2.2. Procedures

The research team designed a semi-structured interview guide involving open-ended questions. This interview guide explored patient genetic mutation history, physical and psychological effects of surgical menopause, sources of information, role of physicians, personal life, and perceptions after surgery (Supplementary material 1). One member of the research team conducted interviews over the phone between June-September 2020 until reaching data saturation. All participants received a research information sheet outlining possible risks involved in participation, and participants provided verbal consent to record interviews. All interviews were audio recorded and transcribed verbatim by a member of the research team. Identifying information was removed during the transcription process to preserve confidentiality.

2.3. Analysis

The Health Belief Model (HBM) was used as a theoretical framework to underpin thematic analysis of previvor narratives. First developed in the 1950s, the HBM is still widely applied to understand health behavior and is based on five cognitive constructs: perceived susceptibility, perceived severity, perceived barriers, perceived benefits, and self-efficacy (Green et al., 2020).

Two primary investigators, both clinicians, first read through all interviews (n = 17) using an immersion/crystallization approach, which involved reading, summarizing, and rereading data (Borkan et al., 1999). The two investigators then analyzed interviews (n = 4) through open coding techniques using ATLAS.ti® version 9.0.1, a software program for qualitative analysis. Based on the analytic process described by Boyatzis (Boyatzis, 1998), thematic analysis allowed for themes and patterns to emerge inductively through cataloguing direct quotes from interview narratives.

The two primary investigators then met with a moderator, a clinician trained in qualitative methods, who was blind to the study hypothesis and interview content. The investigators and moderator explored discrepancies between codes, and they resolved and refined codes. The investigators were randomly assigned the remaining interview transcripts, and they individually applied this universal codebook to all transcripts. The investigators continued to revise the codebook throughout the coding process through an iterative approach as themes emerged. Codes were then explored within and across transcripts to identify patterns and connections between interviews.

3. Results

Twenty-two patients were invited to participate, and 17 (age range 31–46) completed interviews with an acceptance rate of 77% (Table 1). The final codebook was comprised of 31 codes derived inductively from illustrative quotes. Codes were further categorized into ten sub-themes and three major themes: motivating factors for selecting surgical risk reduction options (Supplementary material 2, Table 1), barriers complicating surgical decision-making (Supplementary material, Table 2), and facilitating factors for surgical decision-making (Table 2).

Table 1

| Characteristic                              | Previvors (N = 17) |
|--------------------------------------------|--------------------|
| Age, years                                 | 38 (31–46)         |
| Age at Diagnosis with Genetic Mutation, years | 30 (22–45)        |
| Ethnicity                                  |                    |
| Hispanic                                   | 1 (5.9)            |
| Non-Hispanic or Latinx                     | 16 (94)            |
| Race                                       |                    |
| White                                      | 17 (100)           |
| Genetnic Mutation                          |                    |
| BRCA1                                      | 6 (35)             |
| BRCA2                                      | 7 (41)             |
| Lynch                                      | 3 (18)             |
| Other (MUTYH)                              | 1 (5.9)            |
| Stage of Surgical Intervention             |                    |
| Planning RRS                               | 6 (35)             |
| Completed RRS                              | 5 (29)             |
| Completed RRS-DO                           | 1 (5.9)            |
| Planning RRSO                              | 1 (5.9)            |
| Completed RRSO                             | 3 (18)             |
| Undecided                                  | 1 (5.9)            |
| Prior Mastectomy                           |                    |
| Yes                                        | 7 (41)             |
| No                                         | 10 (59)            |
| Prior Cancer Diagnosis                     |                    |
| Breast cancer                              | 1 (5.9)            |
| Endometrial cancer                         | 2 (12)             |
| None                                       | 14 (82)            |
| Marital Status                             |                    |
| Married                                    | 12 (71)            |
| Single                                     | 5 (29)             |
| Children                                   |                    |
| Yes                                        | 11 (65)            |
| No                                         | 6 (35)             |

Data are median (range) or n (%).
### Table 2

| Theme                                                                 | Sub-theme                                      | Code          |
|----------------------------------------------------------------------|-----------------------------------------------|---------------|
| Facilitating factors for surgical decision-making                     |                                               |               |
| Sources of information regarding genetic diagnosis and risk reduction options |                                               |               |
| Learning about RRS-DO as an option                                   |                                               |               |
| Importance of support with provider                                  |                                               |               |
| Self-advocacy when navigating risk                                   |                                               |               |
| Inevitability of risk reduction                                      |                                               |               |
| Acceptance of risk reduction option                                   |                                               |               |
| Reassurance and confidence in surgical success                        |                                               |               |
| Positive emotions surrounding surgical decision making               |                                               |               |
| Cognitive process of decision-making and putting surgical options     |                                               |               |

#### 3.1. Motivating factors for selecting surgical risk reduction option

#### 3.1.1. Perceptions of ovarian cancer risk

Almost all participants expressed a fear of ovarian cancer as the impetus for pursuing risk reduction. One previvor explained, “I think the ovarian one is so hard because the silent killer concept is very hard for me to grasp. And it’s kind of that one feels more out of control than the other one.” Previvors who were reluctant to undergo RRSO still viewed salpingectomy as a risk-reducing measure. One previvor who underwent RRSO stated, “I think for my sanity I needed to just do what I could do to help myself, and prevent cancer from coming rather than just wait around and see if it happened.”

Still, despite this risk, several previvors weighed the likelihood of an ovarian cancer diagnosis in their decision to undergo RRS-DO. One previvor reflected, “If it didn’t have any adverse effects, I would take it all out... But the other risks of my quality of my life, like so impacted, that I don’t know if it’s worth the risk for me. So with my thirty percent of ovarian cancer and my zero family history of it, I’m not willing to take out every female organ I own.”

#### 3.1.2. Relationships with family

All previvors with children referenced motherhood as the most important factor in their decision to undergo surgical risk reduction. One previvor explained, “Once I found out I was positive, the main factors was just like, ok, I have small children. I want to be around for them. I wanted to do everything that I could. Almost like a panic. Like oh my gosh, nothing can happen to me right now, they’re so little, they need me.”

Several previvors also explained how watching their loved ones navigate cancer motivated them to pursue surgical risk reduction. One previvor recounted her mother’s battle with ovarian cancer: “This is now kind of chronic disease for her, and chronic abdominal pain, and unless there’s some insane tragedy that we’re not anticipating, this is what’s gonna kill her. And we all know it... so it’s always kind of like this afterthought that like, oh yeah, this could be my future unless I do something to prevent it.”

#### 3.1.3. Fear of surgical menopause

Physical and psychological outcomes associated with surgical menopause drove many previvors to select RRS-DO. As one previvor explained, “I was reading everything I could get my hands on. Which basically made my eyes pop out of my head because it wasn’t just vanity things like gaining weight and whatever else. It was also, like, dementia, Alzheimer’s, heart disease. Really crazy, you know, serious stuff.” Almost all previvors also voiced concerns about vaginal dryness, libido, emotional well-being, weight gain, hot flashes, and/or aging.

When discussing hormone replacement therapy (HRT), several previvors who chose RRS-DO felt that the research was “inconclusive” or “too ambiguous for my taste.” Conversely, previvors who chose RRSO viewed menopause symptoms as “better than the alternative” and were more receptive to HRT to mitigate side effects.

Previvors who selected RRSO were more likely to cite the need to undergo two surgeries as a factor in decision making. One of these previvors stated, “My thoughts were I'd rather go through as little surgery as possible, so I'd rather take care of something all at the same time.” On the other hand, one previvor who preferred RRS-DO explained how “it’s a laparoscopic surgery. I can handle it. It’s not that bad and it’ll be like five years apart.”
3.2. Barriers complicating surgical decision-making

3.2.1. Childbearing

Several previvors voiced that they deferred considering risk reduction altogether until after completing childbearing, and a few described psychological distress regarding the loss of fertility accompanying risk reduction. One previvor elucidated, “I feel bad because it’s like this decision is taken away from me because I have to have this surgery done.” Still, although several previvors incorporated surgical risk reduction into their timeline for conceiving or undergoing fertility treatments, maintaining fertility ultimately did not play a role in whether previvors chose to undergo RRS-DO versus RRSO.

3.2.2. Negative emotions surrounding surgical decision-making

Many previvors described their decision-making process as one wrought by confusion and anxiety. Before deciding to undergo RRS-DO, a previvor explained, “I felt like I spent all this time gathering data and I felt very anxious and very nervous and very uneasy.” A few previvors who preferred RRS-DO also voiced concern about insufficient risk reduction. One previvor said, “I don’t know if I’m gonna feel any relief after getting the fallopian tubes out ‘cause right now I don’t know how much of the risk I’m mitigating doing that. But it’s the right path.”

Most previvors also voiced frustration regarding the need for more definitive data and research behind surgical options and ovarian cancer risk, and previvors who were not BRCA1/2 mutation carriers vocalized that a lack of data precluded them from making an informed decision. For example, one previvor stated, “We were sort of desperately looking for more information on the EPCAM mutation and sort of like, more research saying our risks might be a little lower... Every time I’ve asked the doctor it’s been like every research article or any evidence that I’ve found, like ‘there’s just not enough of you to have been researched and we just don’t know yet.’”

3.2.3. Negative interactions with others

Several previvors felt alienated by their providers as they navigated the risk reduction process. As one previvor reflected, her providers failed to provide her with adequate counseling while she weighed her risk reduction options. This previvor felt that “it was ‘ovaries, ovaries, ovaries, now, now, now.’” And also no real discussion about what the rest of my life would look like, as far as going into menopause so early and abruptly.”

3.3. Facilitating factors for surgical decision-making

3.3.1. Role of information

Most previvors actively sought out information and data, which played a central role in their decision to undergo RRS-DO or RRSO. One previvor who underwent RRS-DO stressed her independence in this process: “In terms of the studies, that was extremely important to me. Particularly larger ones and longer ones, ‘cause, you know, that’s where the proof is essentially. And for me as a lawyer I’m very proof and fact driven.” RRS-DO-focused previvors were also more likely to utilize a variety of resources to collect information, from scholarly articles to websites to family and friends. Still, while several previvors found it helpful to explore information on their own, others felt that “there’s just so much clutter” and “it’s just so easy to put out information that’s manipulative.”

3.3.2. Relationships with provider

RRS-DO-focused previvors expressed that shared decision-making with their physicians empowered them to select their preferred risk reduction strategy. One previvor explained how having rapport with her physician encouraged her to pursue RRS-DO: “I’ve also built a relationship with [my doctor] at this point over many, many years. And so I feel very comfortable with her, I like her a lot, I trust her implicitly, and I
Pre- and post-transition experiences with risk reduction among previvors, this strategy is not currently accepted as standard of care. According to the Society of Gynecologic Oncology (SGO), RRS-DO should be offered only to previvors who would otherwise defer or decline risk reduction entirely (SGO Clinical Practice Statement, 2021). In our findings, unlike in a prior study, uncertainty in the effectiveness of RRS-DO did not compel previvors to select RRSO. These previvors remained optimistic that RRS would enable them to await more information from ongoing trials prior to considering oophorectomy. The currently accruing SOROc trial will eventually answer these questions for BRCA1 mutation carriers, but with 20 years of follow up, the results will likely not be timely enough for those currently pursuing surgical risk reduction.

This study has several strengths. To our knowledge, this study is the first in the United States to apply the HBM to ovarian cancer risk reduction and use in-depth interviews to understand why previvors might select RRS-DO over RRSO. Additionally, this comprehensive qualitative approach fully characterized the values and experiences that individually and collectively impacted previvor decision-making. A semi-structured interview format focused on questions that typically arise in patient discussions about surgical prophylaxis while simultaneously allowing for participants to explore ideas that arose organically.

This study also had several limitations. All previvors were recruited from one gynecologic oncology practice at a major academic medical center in New York City and were primarily non-Hispanic white people. As such, findings cannot be generalized to the population of people with HBOC as a whole. Historically, providers have initiated fewer discussions regarding genetic testing with Black and Spanish-speaking Hispanic women, and Black people with BRCA1/2 mutations have had significantly lower rates of RRSO (Cragun et al., 2017; Armstrong et al., 2005; Forman and Hall, 2009). These disparities, evidence of long-standing systemic racism, may explain the lack of ethnic and racial diversity among this study’s participants, although there is irrefutably an unmet need to improve patient education and access to care for people of color who would benefit from risk reduction. Next, findings did not fully capture the way in which breast cancer shaped attitudes towards ovarian cancer risk reduction. The median age of previvors in this study was 38 years, and seven previvors had mastectomies by the time of interview, which together may account for, in part, the low incidence of breast cancer in this particular group.

Ultimately, insights from these previvor narratives can help physicians better understand how each individual patient approaches decision-making and enable physicians to partner with previvors more effectively throughout the risk reduction journey. Improving patient education regarding surgical menopause and prioritizing communication and shared decision-making may build previvor confidence and satisfaction with surgical prophylaxis, allowing each previvor to pursue a risk reduction strategy that best fits individual goals and values. Future studies should employ qualitative methods to better understand factors impacting the ovarian cancer risk-reduction process for people of color.
CHOC Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 19 (1), 99–102.

Harmsen, M.G., Arts-de Jong, M., Hoogerbrugge, N., Maas, A.H.E.M., Prins, J.B., Harmsen, M.G., Harmsen, M.G., Feltmate, C.M., Berkowitz, R.S., Muto, M.G., 2007. Primary fallopian tube cancer. JAMA 293 (14), 1729–1735.

Harmsen, M.G., Arts-de Jong, M., Hoogerbrugge, N., Maas, A.H.E.M., Prins, J.B., Harmsen, M.G., Feltmate, C.M., Berkowitz, R.S., Muto, M.G., 2007. Primary fallopian tube cancer. JAMA 293 (14), 1729–1735.

High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 19 (1), 99–102.

Harmsen, M.G., Arts-de Jong, M., Hoogerbrugge, N., Maas, A.H.E.M., Print, J.B., Bulten, J., Teenenstra, S., Adang, E.M.M., Piek, J.M.J., van Doorn, H.C., van Beurden, M., Mourits, M.J.E., Zweemer, R.P., Gaarenstroom, K.N., Slange, B.F.M., Vos, M.C., van Lonkhuijzen, L.R.G.W., Massuger, L.F.A.G., Hermens, R.P.M.G., de Hullu, J.A., 2015. Early salpingectomy and prophylactic oophorectomy in BRCA1/2 mutation carriers. Surgery 202 (2), 182–291.

Harmsen, M.G., Arts-de Jong, M., Hoogerbrugge, N., Maas, A.H.E.M., Print, J.B., Bulten, J., Teenenstra, S., Adang, E.M.M., Piek, J.M.J., van Doorn, H.C., van Beurden, M., Mourits, M.J.E., Zweemer, R.P., Gaarenstroom, K.N., Slange, B.F.M., Vos, M.C., van Lonkhuijzen, L.R.G.W., Massuger, L.F.A.G., Hermens, R.P.M.G., de Hullu, J.A., 2015. Early salpingectomy and prophylactic oophorectomy in BRCA1/2 mutation carriers. Surgery 202 (2), 182–291.

Harmsen, M.G., Arts-de Jong, M., Hoogerbrugge, N., Maas, A.H.E.M., Print, J.B., Bulten, J., Teenenstra, S., Adang, E.M.M., Piek, J.M.J., van Doorn, H.C., van Beurden, M., Mourits, M.J.E., Zweemer, R.P., Gaarenstroom, K.N., Slange, B.F.M., Vos, M.C., van Lonkhuijzen, L.R.G.W., Massuger, L.F.A.G., Hermens, R.P.M.G., de Hullu, J.A., 2015. Early salpingectomy and prophylactic oophorectomy in BRCA1/2 mutation carriers. Surgery 202 (2), 182–291.

Herndon, A.R., Thomas, J.S., Pate, B., 2005. Why do young breast cancer survivors choose to have their ovaries removed? J. Clin. Oncol. 23 (16), 3540–3545.

Herrmann, A., Hall, A., Proietto, A., 2018. Using the Health Belief Model to explore why women decide for or against the removal of their ovaries to reduce their risk of developing cancer. BMC Women’s Health 18 (1), 184. https://doi.org/10.1186/s12888-017-1050-2.

Hoyland, J.A., Timor-Tritsch, J., Schwartz, P.E., 2005. The role of ultrasound evaluation in the management of premenopausal BRCA1/2 mutation carriers: patients’ perspectives and professionals’ perspectives. Gynecol. Oncol. 106 (2), 305–310. https://doi.org/10.1016/j.ygyno.2014.12.031.

Hrywna, M., Clarke, A., Varma, C., 2003. Women awaiting hysterectomy: a qualitative study of interests or personal relationships that could have appeared to influence surgical decision making in premenopausal BRCA1/2 carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study. J. Med. Genet. 40 (12), 958–962.

Iaconis, K., Fylstra, D., Barakat, R.R., Norton, L., Offit, K., 2002. Risk-reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. Surg. Oncol. 11 (4), 252–259.

Iaconis, K., Fylstra, D., Barakat, R.R., Norton, L., Offit, K., 2002. Risk-reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. Surg. Oncol. 11 (4), 252–259.

Iaconis, K., Fylstra, D., Barakat, R.R., Norton, L., Offit, K., 2002. Risk-reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. Surg. Oncol. 11 (4), 252–259.

Iaconis, K., Fylstra, D., Barakat, R.R., Norton, L., Offit, K., 2002. Risk-reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. Surg. Oncol. 11 (4), 252–259.

Iaconis, K., Fylstra, D., Barakat, R.R., Norton, L., Offit, K., 2002. Risk-reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. Surg. Oncol. 11 (4), 252–259.
associated breast and gynecologic cancer: a multicenter, prospective study. J. Clin. Oncol. 26 (8), 1331–1337.
https://doi.org/10.1200/JCO.2007.18.9626.

King, M.-C., Marks, J.H., Mandell, J.B., 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (5645), 643-646. https://doi.org/10.1126/science.1088759.

Kurman, R.J., Shih, I.-M., 2010. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 34 (3), 433-443. https://doi.org/10.1097/PAS.0b013e3181cf3d79.

Cramer, D.W., Crum, C.P., 2006. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30 (2), 230–236. https://doi.org/10.1097/01.pas.0000180854.28831.77.

Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Medeiros, F., Muto, M.G., 2000. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol. 18 (1), 52-56. https://doi.org/10.1097/jco.2002.6779.

Lu, K.H., Garber, J.E., 2006. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 34 (3), 433-443. https://doi.org/10.1097/PAS.0b013e3181cf3d79.

Muto, M.G., 2000. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol. 18 (14), 2728-2732. https://doi.org/10.1200/JCO.2000.18.14.2728.

Cancer of the Ovary - Cancer Stat Facts. Accessed March 10, 2021. https://seer.cancer.gov/statfacts/html/ovary.html.

CancerPredispositions. Gynecol. Oncol. 107 (2), 159–162. https://doi.org/10.1016/j.ygyno.2007.09.011.

Leprer, K., Garcia, R., Swisher, E., Goff, B., Greer, B., Paley, P., 2002. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 87 (1), 52-56. https://doi.org/10.1016/j.ygyno.2002.6779.

Lu, K.H., Garber, J.E., Cramer, D.W., Welch, W.R., Niloff, J., Schrag, D., Berkowitz, R.S., Leeper, K., Garcia, R., Swisher, E., Goff, B., Paley, P., 2002. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 87 (1), 52-56. https://doi.org/10.1016/j.ygyno.2002.6779.

Lancaster, J., Bethanpowell, C., Kauff, N., Cass, I., Chen, L., Lu, K., Mutch, D., Berchuck, A., Karlan, B., Hertog, T., 2007. Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions. Gynecol. Oncol. 107 (2), 159–162. https://doi.org/10.1016/j.ygyno.2007.09.011.

Rebbeck, T.R., Lynch, H.T., Neuhausen, S.L., Narod, S.A., van’t Veer, L., Garber, J.E., Evans, G., Isaacs, C., Daly, M.B., Matloff, E., Olopade, O.I., Weber, B.L., 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346 (21), 1616–1622. https://doi.org/10.1056/NEJMoa012158.

SEER. Cancer of the Ovary - Cancer Stat Facts. Accessed January 28, 2021. https://www.seer.cancer.gov/statfacts/html/ovary.html.

Evans, G., Isaacs, C., Daly, M.B., Matloff, E., Olopade, O.I., Weber, B.L., 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346 (21), 1616–1622. https://doi.org/10.1056/NEJMoa012158.

SEER. Cancer of the Ovary - Cancer Stat Facts. Accessed January 27, 2021. https://www.seer.cancer.gov/statfacts/html/ovary.html.

Evans, G., Isaacs, C., Daly, M.B., Matloff, E., Olopade, O.I., Weber, B.L., 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346 (21), 1616–1622. https://doi.org/10.1056/NEJMoa012158.

Medeiros, F., Muto, M.G., Lee, Y., Elvin, J.A., Callahan, M.J., Feltmate, C., Garber, J.E., Cramer, D.W., Crum, C.P., 2000. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol. 18 (14), 2728-2732. https://doi.org/10.1200/JCO.2000.18.14.2728.

Cancer of the Ovary - Cancer Stat Facts. Accessed March 10, 2021. https://seer.cancer.gov/statfacts/html/ovary.html.

Medeiros, F., Muto, M.G., Lee, Y., Elvin, J.A., Callahan, M.J., Feltmate, C., Garber, J.E., Cramer, D.W., Crum, C.P., 2000. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol. 18 (14), 2728-2732. https://doi.org/10.1200/JCO.2000.18.14.2728.

Cancer of the Ovary - Cancer Stat Facts. Accessed March 10, 2021. https://seer.cancer.gov/statfacts/html/ovary.html.

Medeiros, F., Muto, M.G., Lee, Y., Elvin, J.A., Callahan, M.J., Feltmate, C., Garber, J.E., Cramer, D.W., Crum, C.P., 2000. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol. 18 (14), 2728-2732. https://doi.org/10.1200/JCO.2000.18.14.2728.